Analyst Expectations for Harmony Biosciences's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided ratings for Harmony Biosciences (NASDAQ:HRMY) within the last quarter, with an average price target of $64.2, implying an upside from the current price of $35.875. The current average has decreased by 12.05% from the previous average price target of $73.00.
June 23, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have provided ratings for Harmony Biosciences (NASDAQ:HRMY) within the last quarter, with an average price target of $64.2, implying an upside from the current price of $35.875.
The average price target of $64.2 for Harmony Biosciences (HRMY) implies an upside from the current price of $35.875. This suggests that analysts are positive about the stock's future performance, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100